The United States Food and Drug Administration (USFDA) has concluded inspection at Cohance Lifesciences’ API manufacturing facility at Jaggaiahpet, Andhra Pradesh, India. The inspection concluded with the issuance of a Form FDA 483 containing five observations. The inspection was conducted from September 14, 2026 to September 19, 2026.
The company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline.
Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.
